Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with chemotherapy for advanced gastric cancer with malignant peritoneal effusion
ChiCTR-OPC-16008296Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Apr 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Planned start Apr 2016; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-OPC-16008296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16008296.